|
Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study |
Minuk LA, Monkman K, Chin-Yee IH, Lazo-Langner A, Bhagirath V, Chin-Yee BH, Mangel JE |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Minuk LA, Monkman K, Chin-Yee IH, Lazo-Langner A, Bhagirath V, Chin-Yee BH, Mangel JE. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leukemia and Lymphoma 2012; 53(1): 57-63 Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols /adverse effects /therapeutic use; Bleomycin /administration & Cost-Benefit Analysis; Dacarbazine /administration & Doxorubicin /administration & Female; Fever /chemically induced; Granulocyte Colony-Stimulating Factor /administration & Hodgkin Disease /drug therapy /economics; Humans; Male; Middle Aged; Neutropenia /chemically induced; Prospective Studies; Risk Factors; Treatment Outcome; Vinblastine /administration & Young Adult; dosage; dosage /adverse effects; dosage /adverse effects; dosage /adverse effects; dosage /adverse effects AccessionNumber 22012001705 Date bibliographic record published 27/06/2012 |
|
|
|